REFERENCES
- Cox JD, Azamia N, Byhardt RW, Shin KH, Enami B, Pajak TF. A randomized phase I-II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2: possible survival benefit with r69.6 Gy in favorable patients with stage III radiation therapy oncology group non small cell lung car-cinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990; 8: 1543-55.
- Green MR Chemotherapy and radiation for stage III non-small cell lung cancer. Am Soc Clin Oncol Educational Book, Dallas 1994; 177-202.
- Le Chevalier T, Arriagada R, Quoix E et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresecable non-small cell lung carcinoma. J Natl Cancer Inst 1991; 83: 417–23.
- Le Chevalier T, Arriagada R, Tarayre M et al. Significant effect of adiuvant chemotherapy on survival in locally advanced non small cell lung carcinoma. J Natl Cancer Inst 1992; 84 ( letter): 58.
- Dillman RO, Seagren SL, Propert KJ et al. A random-ized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 1990; 323: 940–5.
- Morton RF, Jett JR, McGinnis WL et al. Thoracic radia-tion therapy alone compared with combined chemoradiother-apy for locally unresectable non-small cell lung cancer. Ann Intern Med 1991; 115: 681–6.
- Troyò MG, Minatel E, Veronesi A et al. Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma. A ran-domized study. Cancer 1990; 65: 400–4.
- Coppola F, Capo A, Van Koten M et al. Phase II study: navelbine (NVB) + cisplatin (P) in non-operable non-small cell lung cancer (NSCLC) stage IIIB-IV. Ann Oncol 1994; 5 (suppl 8): 792 (Abstr).
- Jacoulet P, Dubiez A, Depierre A, Pugin JF, Pernet D. One-week versus 3-weeks intervals in the administration of cisplatin in combination with vinorelbine: a randomized study in non small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1992; 11: 1013 (Abstr).
- Le Chevalier T, Brisgand D, Douillard JY et al. Randomized study of vinorelbine and cisplatin versus vinde-sine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12 (2): 360-7.
- Belani CP. Multimodality management of regionally advanced non small cell lung cancer. Sem Oncol 1993; 20 (4): 302–14.
- Tomirotti M, Gramegna G, Mantellini P et al. concur-rent carboplatin (CBDCA), vindesine (VDS) and radiothera-py in stage III non small cell lung cancer (NSCLC). Tumori 1993; 79: 49–57.
- Green MR. Induction chemotherapy prior to definitive radiation for stages IIIA and IIIB non-small cell lung cancer. Lung Cancer 1993; 9 (2): S39–S47.
- Vogl SE, Zaravinos T, Kaplan BH. Toxicity of cis-diamminedichloroplatinum II given in a two-hour outpatient regimen of diuresis and hydration. Cancer 1980; 45: 11–15.